

Company Name: HEALIOS K.K.
Representative: Hardy TS Kagimoto, Chairman & CEO
(TSE Growth Code: 4593)

Notice Regarding the Termination of the Business and Capital Alliance Agreement with Nikon Corporation

HEALIOS K.K. (“Healios”) hereby announce that, as of today, we have reached an agreement with Nikon Corporation (hereinafter referred to as “Nikon”) to terminate the business and capital alliance (hereinafter referred to as “the Alliance”). This decision was resolved at the Executive Committee Meeting of our company held today. Consequently, the Business and Capital Alliance Agreement dated February 22, 2017 (hereinafter referred to as “the Alliance Agreement”) will be terminated.

On February 22, 2017, as announced in the "[Announcement of Business and Capital Alliance Contract with Nikon Corporation](#)", we entered into the Alliance Agreement with Nikon to promote business initiatives aimed at the commercialization of regenerative medicine and the expansion of the industry. However, after re-examining the changes in the business environment and the strategic direction of both companies' technologies and businesses, both parties have agreed to terminate the Alliance. Moving forward, each company will independently pursue their respective strengths.

Healios group has decided to expand its business operations as a Contract Development and Manufacturing Organization (CDMO) starting in 2025. As announced on July 16, 2025, in the "[Notice of Selection for FY2024 Supplementary Budget: “Subsidy Program to Support Capital Investment in Regenerative, Cell, and Gene Therapy Manufacturing Facilities” by METI](#)", we are preparing the infrastructure necessary to develop a global CDMO business for regenerative and cellular medicine.

This matter will have no impact on our consolidated financial results for the fiscal year ending December 2025. Should there be any matters requiring disclosure, we will promptly make an announcement.

About Healios:

HEALIOS K.K. is Japan’s leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. It aims to offer new therapies for patients suffering from diseases without effective treatment options. Healios is a pioneer in the development of regenerative medicines in Japan and owns proprietary, global platforms utilizing both somatic stem cells and iPS cells.

In the somatic stem cell field, Healios is developing invimestrocel (HLCM051), a proprietary cell product comprised of multipotent adult progenitor cells (“MAPCs”) derived from the bone marrow of healthy adult donors. Invimestrocel has been shown to exhibit powerful anti-inflammatory and immunomodulatory properties with applicability in a range of disease states, has been tested in hundreds of patients in late stage clinical trials, is manufactured consistently at scale in 3D bioreactors, and has demonstrated both safety and suggested efficacy in

hundreds of patients across multiple indications. Healios is seeking to advance invivestrocel on a global basis for ischemic stroke, ARDS, and trauma.

In the iPSC regenerative medicine field, Healios is developing HLCN061, a next generation NK cell treatment for solid tumors that has been functionally enhanced through gene-editing. These cells have demonstrated robust anti-tumor efficacy in animal models, benefit from a scalable 3D bioreactor manufacturing process, and are currently being prepared for initial human testing in collaboration with Akatsuki Therapeutics. The company has also established a proprietary, gene-edited “universal donor” induced pluripotent stem cell line to develop next generation regenerative treatments in immuno-oncology, ophthalmology, liver diseases, and other areas of severe unmet medical need.

Healios was established in 2011 and has been listed on the Tokyo Stock Exchange since 2015 (TSE Growth: 4593). <https://www.healios.co.jp/en>

Contact:
IR & PR Division
HEALIOS K.K.
E-mail: ir@healios.jp